Copyright © 2007 The International Association for Biologicals Published by Elsevier Ltd.
Review
Impact of vCJD on blood supply
Received 16 November 2006;
| Referred to by: | Blood-transmitted prions and variant Creutzfeldt–Jakob disease Biologicals, Volume 35, Issue 2, April 2007, Pages 75-77 George F. Grady, Girish N. Vyas | |
References and further reading may be available for this article. To view references and further reading you must purchase this article.
Abstract
Variant Creutzfeldt–Jakob disease (vCJD) is an at present inevitably lethal neurodegenerative disease which can only be diagnosed definitely post mortem. The majority of the approximately 200 victims to date have resided in the UK where most contaminated beef materials entered the food chain. Three cases in the UK demonstrated that vCJD can be transmitted by blood transfusion. Since BSE and vCJD have spread to several countries outside the UK, it appears advisable that specific risk assessments be carried out in different countries and geographic areas. This review explains the approach adopted by Germany in assessing the risk and considering precautionary measures. A fundamental premise is that the feeding chain of cattle and the food chain have been successfully and permanently cleared from contaminated material. This raises the question of whether transmissions via blood transfusions could have the potential to perpetuate vCJD in mankind. A model calculation based on actual population data showed, however, that this would not be the case. Moreover, an exclusion of transfusion recipients from blood donation would add very little to the safety of blood transfusions, but would have a considerable impact on blood supply. Therefore, an exclusion of transfusion recipients was not recommended in Germany.
Keywords: Bovine spongiform encephalopathy; Variant Creutzfeldt–Jakob disease; Blood supply; Risk assessment
Abbreviations: AFSSAPS, Agence Française de Sécurité Sanitaire des Produits de Santé (French medicinal products authority); BSE, bovine spongiform encephalopathy (degenerative neurological disease in cattle caused by prions); CJD, Creutzfeldt–Jakob disease (TSE disease in humans, transmissible via medicinal products (iatrogenic) or occurring sporadically); FFP, “fresh frozen plasma”(plasma for transfusion); GBR, “geographical BSE risk”: classification of countries into one of four risk classes (GBR I–IV) by the Scientific Steering Committee of the European Commission; GSS, Gerstmann-Sträussler-Scheinker syndrome (a human TSE); HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus (agent of AIDS); i.c., intracerebral; IU, infectious unit; i.v., intravenous; M, methionine; PMCA, protein misfolding cyclic amplification (method for amplification of PrPSc in vitro); PrP, prion protein; PrPc, cellular, physiological form of the prion protein (c = cellular); PrPSc, pathological form of the prion protein (Sc = Scrapie); RBCC, red blood cell concentrate; SCMPMD, Scientific Committee on Medicinal Products and Medical Devices of the European Commission; SRM, specified risk material (bovine materials in which the BSE agent can be detected in high concentrations (brain, spinal cord etc.)); SSC, Scientific Steering Committee of the European Commission; TSE, transmissible spongiform encephalopathy (disease of the brain, generic term for neurological disorders caused by prions); UK, United Kingdom (Great Britain and Northern Ireland); V, valine; vCJD, variant Creutzfeldt–Jakob disease (human TSE caused by the BSE agent, first described in 1996)
Article Outline
- 1. Introduction
- 2. The Occurrence of BSE
- 3. BSE in Germany
- 4. BSE in small ruminants
- 5. The occurrence of vCJD
- 6. Estimation of the extent of the spread of vCJD
- 7. Risk of vCJD transmission through blood (secondary infections)
- 8. Reduction of TSE in the manufacture of blood products
- 9. Blood components for transfusion, leukocyte depletion
- 9.1. Red blood cell concentrates (RBCC)
- 9.2. Platelet concentrates (PC)
- 9.3. Plasma for transfusion (“Fresh Frozen Plasma, FFP”)
- 10. Industrial products from pool plasma, nanofiltration
- 11. Optimal use of blood products
- 12. Diagnosing vCJD: screening tests
- 13. Exclusion of persons from donating blood
- 14. Impact of deferrals on the blood supply
- 15. Summary and conclusions
- Acknowledgements
- References






E-mail Article
Add to my Quick Links

Cited By in Scopus (2)






